Compare · DFTX vs IMCC
DFTX vs IMCC
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and IM Cannabis Corp. (IMCC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and IMCC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $6.02B, about 3054.5x IMCC ($2.0M).
- DFTX has been more active in the news (15 items in the past 4 weeks vs 8 for IMCC).
- DFTX has more recent analyst coverage (7 ratings vs 3 for IMCC).
- Company
- Definium Therapeutics Inc.
- IM Cannabis Corp.
- Price
- $44.77+3.55%
- $0.11+6.28%
- Market cap
- $6.02B
- $2.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 15
- 8
- Recent ratings
- 7
- 3
IMCC
IM Cannabis Corp.
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers strains under the Roma, Dairy Queen, London, Tel Aviv, Paris, and Pandora Box brands; and CBD oil products under the IMC brand. The company also offers its intellectual property related services to the medical cannabis industry. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.
Latest DFTX
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Latest IMCC
- SEC Form 6-K filed by IM Cannabis Corp.
- IM Cannabis Announces Intention to Complete 30:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance
- SEC Form 6-K filed by IM Cannabis Corp.
- IM Cannabis Enters into Agreement to Sell IMC Holdings and European- Focused Assets
- IM Cannabis Corp. Announces Second Quarter and First Half 2026 Financial Results
- SEC Form 6-K filed by IM Cannabis Corp.
- SEC Form 6-K filed by IM Cannabis Corp.
- IM Cannabis Raises US$250,000 of Gross Proceeds in Convertible Note Financing
- SEC Form 6-K filed by IM Cannabis Corp.
- IM Cannabis Provides Corporate Update